BF Biosciences Limited (PSX:BFBIO)

Pakistan · Delayed Price · Currency is PKR

148.13

+5.52 (3.87%)

At close: Jun 22, 2026

-11.30% (1Y)

Market Cap	13.08B -18.4%
Revenue (ttm)	8.86B +78.7%
Net Income	591.76M +51.1%
EPS	6.70 +27.8%
Shares Out	88.33M
PE Ratio	22.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,423
Open	145.00
Previous Close	142.61
Day's Range	142.60 - 150.26
52-Week Range	124.00 - 189.97
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 22, 2026

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul... [Read more]

Industry Pharmaceutical Preparations

Founded 2006

Employees 535

Stock Exchange Pakistan Stock Exchange

Ticker Symbol BFBIO

Full Company Profile

Financial Performance

In fiscal year 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.

Financial Statements